SuperGen Orathecin Review Extended After Large Data Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to review data from 1,000-patient first-line trial in pancreatic cancer that failed to meet the primary endpoint of survival. User fee date for second-line indication has been extended to Feb. 26, 2005.
You may also be interested in...
Supergen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
Withdrawal of NDA for second-line treatment of pancreatic cancer is “most prudent course of action,” firm says following talks last week with FDA. Supergen is moving ahead with a combination trial with gemcitabine.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.